THRD Third Harmonic Bio, Inc.

Nasdaq thirdharmonicbio.com


$ 5.38 $ 0.00 (-0.09 %)    

Wednesday, 30-Jul-2025 15:59:57 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 5.38
$ 5.41
$ 5.37 x 5,200
$ 5.48 x 4,549
-- - --
$ 3.18 - $ 16.02
1,417,958
na
242.79M
$ 0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2025 03-31-2025 10-Q
2 03-27-2025 12-31-2024 10-K
3 11-07-2024 09-30-2024 10-Q
4 08-08-2024 06-30-2024 10-Q
5 05-15-2024 03-31-2024 10-Q
6 03-26-2024 12-31-2023 10-K
7 11-09-2023 09-30-2023 10-Q
8 08-10-2023 06-30-2023 10-Q
9 05-11-2023 03-31-2023 10-Q
10 03-29-2023 12-31-2022 10-K
11 11-09-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 third-harmonic-bio-q1-eps-035-misses-029-estimate

Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of ...

 third-harmonic-bio-stock-is-up-40-monday-whats-happening

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolu...

Core News & Articles
Market-Moving News for April 14th
04/14/2025 11:24:27

AAPL: 6% | Apple shares are trading higher after the Trump administration announced tariff exemptions for smartphones. THRD: 40...

 third-harmonic-bio-announces-plan-of-dissolution-with-payout-between-2466m2554m-pending-stockholder-approval

Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at th...

 stifel-downgrades-third-harmonic-bio-to-hold-lowers-price-target-to-5

Stifel analyst Alex Thompson downgrades Third Harmonic Bio (NASDAQ:THRD) from Buy to Hold and lowers the price target from $...

 third-harmonic-bio-fy-2024-gaap-eps-109-beats-118-estimate

Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(...

 third-harmonic-bio-initiates-strategic-review-lays-off-50-staff-citing-competitive-landscape

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while...

 morgan-stanley-downgrades-third-harmonic-bio-to-equal-weight-lowers-price-target-to-5

Morgan Stanley analyst Michael Ulz downgrades Third Harmonic Bio (NASDAQ:THRD) from Overweight to Equal-Weight and lowers th...

 raymond-james-downgrades-third-harmonic-bio-to-market-perform

Raymond James analyst Laura Prendergast downgrades Third Harmonic Bio (NASDAQ:THRD) from Outperform to Market Perform.

 third-harmonic-bio-says-data-from-its-phase-1-trial-of-thb335-in-healthy-volunteers-supports-the-advancement-into-a-phase-2-trial-in-chronic-spontaneous-urticaria-the-company-is-initiating-a-strategic-review-process-to-run-in-parallel-with-phase-2-readiness-activities-to-identify-opportunities-to-maximize-shareholder-value

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION